TY  - JOUR
A1  - Lagging, Martin
A1  - Askarieh, Galia
A1  - Negro, Francesco
A1  - Bibert, Stephanie
A1  - Söderholm, Jonas
A1  - Westin, Johan
A1  - Lindh, Magnus
A1  - Romero, Ana
A1  - Missale, Gabriele
A1  - Ferrari, Carlo
A1  - Neumann, Avidan U.
A1  - Pawlotsky, Jean-Michel
A1  - Haagmans, Bart L.
A1  - Zeuzem, Stefan
A1  - Bochud, Pierre-Yves
A1  - Hellstrand, Kristoffer
A1  - Group, DITTO-HCV Study
T1  - Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
T2  - PLoS One
N2  - Background: High baseline levels of IP-10 predict a slower first phase decline in HCV RNA and a poor outcome following interferon/ribavirin therapy in patients with chronic hepatitis C. Several recent studies report that single nucleotide polymorphisms (SNPs) adjacent to IL28B predict spontaneous resolution of HCV infection and outcome of treatment among HCV genotype 1 infected patients. Methods and Findings: In the present study, we correlated the occurrence of variants at three such SNPs (rs12979860, rs12980275, and rs8099917) with pretreatment plasma IP-10 and HCV RNA throughout therapy within a phase III treatment trial (HCV-DITTO) involving 253 Caucasian patients. The favorable SNP variants (CC, AA, and TT, respectively) were associated with lower baseline IP-10 (P = 0.02, P = 0.01, P = 0.04) and were less common among HCV genotype 1 infected patients than genotype 2/3 (P<0.0001, P<0.0001, and P = 0.01). Patients carrying favorable SNP genotypes had higher baseline viral load than those carrying unfavorable variants (P = 0.0013, P = 0.029, P = 0.0004 respectively). Among HCV genotype 1 infected carriers of the favorable C, A, or T alleles, IP-10 below 150 pg/mL significantly predicted a more pronounced reduction of HCV RNA from day 0 to 4 (first phase decline), which translated into increased rates of RVR (62%, 53%, and 39%) and SVR (85%, 76%, and 75% respectively) among homozygous carriers with baseline IP-10 below 150 pg/mL. In multivariate analyses of genotype 1-infected patients, baseline IP-10 and C genotype at rs12979860 independently predicted the first phase viral decline and RVR, which in turn independently predicted SVR. Conclusions: Concomitant assessment of pretreatment IP-10 and IL28B-related SNPs augments the prediction of the first phase decline in HCV RNA, RVR, and final therapeutic outcome.
Y1  - 2011
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/22661
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30-115060
SN  - 1932-6203
N1  - Copyright: © 2011 Lagging et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
VL  - 6
IS  - (2): e17232
ER  -